Experimental study of inhibitory effect of compound Shenqitang on gastric and colorectal carcinomas
QIAN Jingjing,SHEN Hongxun,LU Fei,et al(Department of General Surgery,Affiliated Hospital of Nantong University,Nantong 226001)
Objective:To investigate the mechanism of therapeutic effect of compound Shenqitang on the gastric and col-orectal carcinomas.Methods:Several experiments had been done,including:(1) the inhibitory effect of compound Shenqitang on human gastric adenocarcinoma cell line in vitro;(2) its inhibitory effects on Wistar rat gastric adenocarcinoma induced by MNNG;and(3) its inhibitory effect on the hepatic metastases of colorectal carcinoma in mice.Results:(1)Obvious inhibitory effects of compound Shenqitang had been found on the cell division and colony form of human gastric adenocarcinoma cell line BGC-823 in vitro.The LC50 was 0.007g crude drug/ml in colony form experiment.The drug had potent killing effect in higher concentration,with LC50 of 0.048g crude drug/ml;(2)The incidence of gastric adenocarcinoma in the experimental group(6.9%) was significantly lower than that in the control group(58.9%).The positive rates of PCNA and cyclin D1 in the experimental group were 13.88%(5/36) and 22.86%(8/35),which were significantly lower than those in the control group(P0.01);(3)Compound Shenqitang inhibited hepatic metastases of colorectal carcinoma in mouse model.Nm23H1-NDPK positive expression rate(66.67%) was significantly higher in the experimental group than that(16.67%) in the control group(P0.05).Conclusion:Compound Shenqitang can effectively kill the human gastric adnocarcinoma cell line BGC-823 in vit-ro,inhibit the incidence of the gastric adenocarcinoma induced by MNNG in Wistar rats,and inhibit hepatic metastasis of colon carcinoma in mouse model.
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.